GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2007

Gene Logic to Reposition Lundbeck Candidates

  • Gene Logic will work with H. Lundbeck to reposition some of the latter’s drug candidates. These compounds were discontinued or de-prioritized in clinical trials for reasons other than safety, according to the companies.

    The drug repositioning agreement provides for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lundbeck's contribution as the originator of the compound. Gene Logic retains the option to exclusively license any candidate for which Gene Logic identifies a potential new use and Lundbeck chooses not to pursue. In such a case Lundbeck will be payed success-based milestones and royalties.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?